Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Clinical trial NCT01740557 · COMPLETED

Trial details

NCT number: NCT01740557
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Metastatic Melanoma Stage III Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7

Start date: 2015-01-28
Primary completion: 2023-04-21
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.